| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURONEURO.2005.02.006 |
| P698 | PubMed publication ID | 16139175 |
| P50 | author | Roger S McIntyre | Q88039086 |
| P2093 | author name string | Björn Paulsson | |
| Martin Brecher | |||
| Jamie Mullen | |||
| Karin Huizar | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| haloperidol | Q251347 | ||
| P304 | page(s) | 573-585 | |
| P577 | publication date | 2005-04-18 | |
| P1433 | published in | European Neuropsychopharmacology | Q15286536 |
| P1476 | title | Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial | |
| P478 | volume | 15 |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q34349862 | Acute akathisia with quetiapine: A case report and review of literature |
| Q35236966 | Acute and long-term treatment of mania. |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q34582587 | Akathisia: problem of history or concern of today |
| Q24656287 | Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial |
| Q35073872 | Antimanic treatments in bipolar mixed states |
| Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
| Q41361163 | Antipsychotic effects of quetiapine in naturalistic long term follow up study |
| Q37111491 | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review |
| Q38077281 | Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice |
| Q38749001 | Assessment and management of agitation in psychiatry: Expert consensus |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
| Q57738604 | Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika |
| Q33448290 | Bipolar disorder. |
| Q36390795 | Bipolar disorder: historic perspective, current pharmacologic treatment options and a review of quetiapine |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q24814468 | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
| Q47756799 | Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q52673200 | Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. |
| Q36274272 | Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review |
| Q36519345 | Economics of atypical antipsychotics in bipolar disorder: a review of the literature |
| Q38003197 | Efficacy of antimanic treatments in mixed states |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q34994544 | Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q36618022 | Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study. |
| Q38069670 | Eficcacy of extended release quetiapine in affective symptoms |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q36762209 | Evolving trends in the long-term treatment of bipolar disorder |
| Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
| Q47381585 | Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study |
| Q37763161 | Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q53083364 | Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis. |
| Q43986382 | Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q34300315 | Mania: diagnosis and treatment recommendations |
| Q36929705 | New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania |
| Q43042813 | Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder |
| Q44017165 | Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania |
| Q36361982 | Polytherapy in bipolar disorder |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q39674704 | Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. |
| Q38237319 | Quetiapine extended release for the treatment of bipolar disorder |
| Q36818095 | Quetiapine for acute mania in bipolar disorder |
| Q48686688 | Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy |
| Q37429709 | Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies |
| Q27499305 | Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies |
| Q34272859 | Quetiapine: a pharmacoeconomic review of its use in bipolar disorder |
| Q36316977 | Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q36807427 | Retrospective analysis of factors associated with quetiapine dosage in the acute and subsequent six-month maintenance treatment of bipolar disorders |
| Q38413932 | Revisiting loxapine: a systematic review |
| Q37803220 | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder |
| Q36780394 | Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial |
| Q38350551 | Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). |
| Q83332626 | Spotlight on quetiapine in acute mania and depression associated with bipolar disorder |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q36458469 | The role of quetiapine in the treatment of bipolar disorder |
| Q37468555 | The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q44930054 | Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q36393992 | Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders |
| Q57550164 | Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6 |
| Q46810268 | Validity of conclusions about quetiapine |
| Q37726041 | Valproate and neuroprotective effects for bipolar disorder |
| Q86485574 | Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort |
| Q46202394 | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study |
| Q86086565 | [Bipolar disorder: inter-episode symptoms] |
| Q86086575 | [Mixed states] |
Search more.